Key result
The efficacy of paracetamol in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants could not be determined due to a truncated abstract.
Why the study?
Does paracetamol improve outcomes in preterm infants with patent ductus arteriosus who are ibuprofen-resistant or contraindicated?
Does paracetamol improve outcomes in preterm infants with patent ductus arteriosus who are ibuprofen-resistant or contraindicated?
Paracetamol is being explored as an alternative treatment for patent ductus arteriosus in preterm infants when standard cyclooxygenase inhibitors are contraindicated or ineffective.
Answers are grounded in this paper and cite their sources.
Insufficient evidence to guide paracetamol for resistant PDA; leaves open its role pending complete prospective data.
The most commonly used drugs for closure of a haemodynamically significant patent ductus arteriosus (hsPDA) are cyclooxygenase inhibitors, mainly indomethacin and intravenous/oral ibuprofen. In contrast to high closure rates, several adverse effects have been reported with such medications, including gastrointestinal bleeding and perforation, weakened platelet aggregation, hyperbilirubinaemia and renal failure.1 ,2 The role of paracetamol as an …
No takes yet. Share an insight, caveat, or question.
Öncel et al. (2012) studied Patent ductus arteriosus (hsPDA). Paracetamol was evaluated. The efficacy of paracetamol in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants could not be determined due to a truncated abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: